Author Archives: Ana Pamplona, PhD

New CAR T-cell Therapy Seen to Induce Lasting Remission in Advanced Multiple Myeloma Patients

An ongoing Phase 1 trial testing a novel CAR T-cell therapy has shown promising results in relapsed or treatment-resistant (refractory) multiple myeloma patients. The new anti-BCMA therapy, called LCAR-B38M, induced tumor responses in all 35 enrolled patients, and 94 percent experienced complete or near complete durable remissions. The findings were recently presented…